Evaluating the antifracture efficacy of bisphosphonates.
Oral bisphosphonate dosing schedules have evolved from the original daily regimens to weekly (alendronate and risedronate) and monthly (risedronate and ibandronate) regimens. Intravenous (i.v.) bisphosphonates are administered less frequently-quarterly ibandronate injection and yearly zoledronic aci...
Auteurs principaux: | Pazianas, M, Epstein, S, Zaidi, M |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2009
|
Documents similaires
-
Antifracture agents for prostate cancer patients on androgen deprivation therapy
par: Bhupendra P Singh, et autres
Publié: (2010-01-01) -
The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
par: Angelo Fassio, et autres
Publié: (2024-04-01) -
Safety of bisphosphonates.
par: Pazianas, M, et autres
Publié: (2011) -
Bisphosphonates and bone quality.
par: Pazianas, M, et autres
Publié: (2014) -
Atrial fibrillation and bisphosphonate therapy.
par: Pazianas, M, et autres
Publié: (2010)